(1) To define the minimal clinically important difference (MCID) of the Velopharyngeal Insufficiency (VPI) Effects on Life Outcomes (VELO) instrument, and (2) to test for the change in quality of life (QOL) after VPI surgery.
Introduction
Velopharyngeal insufficiency (VPI) affects speech, swallowing, and many psychosocial aspects of life. The VPI Effects on Life Outcomes (VELO) instrument, with youth and parent versions, is a quality of life (QOL) instrument that was developed to capture the effects of VPI on children's lives. 1 Previous studies have documented the VELO instrument's validity, reliability, and responsiveness, 1-3 but the minimal clinically important difference (MCID) 4 has not yet been defined for this instrument. The MCID analysis defines the smallest change in QOL that reaches clinical importance and is an important step in instrument assessment. 5 A primary goal for the VELO instrument is to enable rigorous measurement of the effects of VPI treatment on QOL. Previous studies of life effects of VPI treatment have shown improvement in a small sample with a functional status measure. 6 Additionally, in a previous short-term case series, we found significant improvements in short-term QOL measured by the VELO instrument. 2 While these studies have provided a foundation for future analyses, neither study utilized a control group. Data from a comparison group provide further evidence that measured changes in QOL are associated with the intervention rather than just temporal trends or natural course of the disorder, and they allow an adjustment for confounders. 7 The surgical treatment of VPI includes palatal and/or pharyngeal procedures. Furlow palatoplasty utilizes mucosal and myomucosal Z-plasty to lengthen the palate and reorient the levator veli palatini. 8 Sphincter pharyngoplasty utilizes rotational myomucosal flaps based on the palatopharyngeus and superior constrictors to augment the posterior pharyngeal wall and laterally narrow the velopharynx. The pharyngeal flap utilizes a superiorly based myomucosal flap to obturate the central velopharynx. The pharyngeal flap is not used at this institution. Nonsurgical management typically involves the use of an intraoral appliance (ie, obturator) or conservative measures such as speech therapy alone.
The primary aims of this study were to (1) define the VELO instrument's MCID and (2) test the effects of VPI surgery on QOL at 1 year after treatment using the validated VELO instrument. Secondary aims included analyses of subgroups and VELO subscales.
Methods

Study Subjects
This prospective cohort study enrolled subjects with VPI from Seattle Children's Hospital VPI Clinic as previously described. 2 English-speaking children (ages 3-22 years) were enrolled from January 2010 to February 2012. Exclusion criteria included severe intellectual disability (n = 3), VPI surgery within 6 months prior to enrollment (n = 2), treatment with maxillomandibular advancement procedures (n = 4), and incomplete follow-up (ie, not reaching 12month time point) at the close of the study (n = 23). The study was approved by the Institutional Review Board at Seattle Children's Hospital, and all parents provided written informed consent.
Subjects completed questionnaires at enrollment during a VPI clinic visit. Medical records were monitored to identify subjects' treatment dates. Follow-up questionnaires were sent by mail 12 months after treatment for those treated with surgery or an obturator. The mean time from enrollment to surgical or obturator treatment was 3 months for the first 45 subjects treated. Therefore, follow-up questionnaires were sent by mail 15 months after enrollment for those not undergoing surgery or obturator treatment to match the outcome time point on the time from enrollment.
VPI Treatment Groups
After an initial evaluation, surgical and nonsurgical treatment options were discussed, and patients proceeded into 1 of 3 treatment groups: (1) VPI surgery, (2) other treatment, or (3) no treatment. The VPI surgery group included patients undergoing either Furlow palatoplasty or sphincter pharyngoplasty (n = 32). Details about our institution's diagnosis and treatment protocols have been described. 9 The other treatment group included patients treated with an obturator or oronasal fistula repair (n = 7). Subjects who elected prosthetic treatment were referred to the dental service for obturator fitting. Obturators were adjusted until the speech and language pathologist felt that VPI was adequately treated. Some subjects did not undergo functional palatal surgery but rather only oronasal fistula repair and were also grouped in the other treatment group. The no treatment group included patients (and families) who deferred these specific VPI treatments for a variety of reasons such as perceived mild speech dysfunction or social reasons (n = 18). All subjects with velopharyngeal mislearning were eligible for speech therapy, regardless of the specific VPI treatment.
Patient-reported Outcomes
The VELO instrument is a VPI-specific QOL measure that was developed using focus groups, which provide face validity. 1 It includes a 26-item parent version (VELO-P) and a 23-item youth version (VELO-Y) for children 8 years and older. The total score (VELO-P total or VELO-Y total) ranges from 0 to 100, with 100 representing the highest QOL. Subscales are scored similarly and include speech, swallowing, situational difficulty, perception by others, and emotional impact for both the VELO-P and VELO-Y and also include caregiver impact for the VELO-P. The instrument was previously tested for reliability, validity, and responsiveness to change in QOL 3 months after treatment. [1] [2] [3] Parents were asked if there had been an interval change in their child's QOL with a global rating of change instrument. On this instrument, parents reported how much better or worse their child's QOL was on a 13-point Likert-type scale, ranging from ''a great deal better'' (16) to ''a great deal worse'' (-6) . A score of 0 indicated that QOL was ''about the same'' over the interval. A similar instrument has been previously used to determine the MCID in other QOL instruments. 4, 10, 11 Parents also reported speech ratings of change, swallowing ratings of change, and situational difficulty ratings of change measures which are analogous to the global rating of change.
Data Analysis MCID analysis. The primary MCID analysis used the global rating of change as an anchor for the MCID of the VELO-P total score. The global rating of change measure was used to categorize subjects according to the degrees of clinical change in QOL at follow-up. Subjects with global rating of change scores of 21, 0, and 11 were considered to have no clinically important change in QOL. Subjects with global rating of change scores of 23, -2, 12, and 13 were considered to have a minimal clinically important change in QOL, and these scores were used to anchor our definition of the MCID. 11 The mean magnitude change in VELO-P total scores of these subjects, regardless of treatment group, was defined as the MCID of the VELO instrument. We used the VELO-P total score for the primary assessment of the MCID because parents completed the instrument for all children regardless of age (n = 32; missing data, n = 5), while the VELO-Y was completed only for a subset of subjects aged 8 years and older (n = 8). The association between change in the VELO-P total score and the global rating of change was tested with the test for trend and modeled with multivariate linear regression.
Secondary MCID analyses were performed in the subgroup of youth scores (VELO-Y total) and on the subscales of the VELO-P using the rating of change instruments for speech, swallowing, and situational difficulty. For example, the MCID for the VELO-P speech subscale was calculated with anchors (-3, -2, 12, 13) from the speech rating of change instrument.
As a tertiary MCID analysis, we calculated the MCID using a statistical distribution method 12 as 0.2 to 0.5 times the baseline VELO-P standard deviation. In other words, using this distribution method, we defined the MCID as an effect size of 0.2 (small but meaningful effect) to an effect size of 0.5 (moderate effect). 13 Change in the VELO score with VPI surgery. The VELO-P total score was tested for change from baseline to 12-month follow-up with a paired t test for the VPI surgery group and for the no treatment group. The change in the VELO-P total score was calculated for each subject as the difference between baseline and follow-up in which a positive change score denotes improvement. The difference in change in VELO-P total scores was tested between the VPI surgery group and the no treatment group with the Student t test. Secondary analyses were similarly conducted for each of the subscales of the VELO-P. We do not present analyses of change in the VELO-Y score with VPI surgery because the sample of youth-completed questionnaires in that group was small.
The association between VPI surgery status (VPI surgery vs no treatment) and change in the VELO-P total score was tested using multivariate linear regression, adjusting for a priori hypothesized confounders. Potential confounders include age, VPI severity, compensatory misarticulations, size of the velopharyngeal gap on nasendoscopy, and subjects' need for special education. Confounders were included in the final multivariate model if their inclusion appreciably altered (10%) the association of VPI surgery status and change in the VELO-P total score, a validated method of adjusting for confounders in explanatory regression models. 14 All statistical analyses were performed with Stata 12 (College Station, Texas, USA). For primary analyses, P values \.05 were considered statistically significant. For secondary analyses, the Bonferroni P value correction was applied.
Results
Eighty-nine patients were potentially eligible for participation. Thirty-two patients were excluded based on the criteria noted in the Methods section. Enrollment included 57 patients (mean age, 6.8 6 4.0 years) and their parents. All parents completed the VELO-P (n = 57), and patients older than 8 years also completed the VELO-Y (n = 15). The demographic and clinical characteristics of each treatment group were similar ( Table 1 ) except for VPI severity (P \ .05). A large proportion of subjects in each group had a history of cleft palate with or without a cleft lip. Follow-up was obtained for 22 of 32 (69%) patients of the VPI surgery group, 4 of 7 (57%) of the other treatment group, 11 of 18 (61%) of the no treatment group, and 8 of 15 (53%) patients older than 8 years.
MCID and the Relationship between the VELO and the Global Rating of Change
Subjects from all treatment groups were included in the MCID analysis. The distribution of VELO-P and VELO-Y scores across the global rating of change scores is shown in Table 2 . The mean global rating of change score was 2.6 6 2.6, and the mean change in the VELO-P total score was 16 6 15. Eleven parents scored the global rating of change as 21, 0, or 11 corresponding to no change in QOL, and their mean change in the VELO-P total score was 11 6 14. Six parents scored the global rating of change as 23 (n = 0), -2 (n = 0), 12 (n = 2), or 13 (n = 4) corresponding to the anchor for the MCID, and their mean magnitude change in the VELO-P total score was 15 6 13.
Higher global rating of change scores were associated with larger improvements in the mean VELO-P total score (P = .02). Linear regression of change in the VELO-P total score with the global rating of change as the independent variable showed that each increment in the global rating of change score was associated with a 3-point improvement (95% confidence interval [CI], 1-5; P = .006) in the VELO-P total score (Figure 1) . The mean change in the VELO-P total score for the MCID group based on linear regression was 21 (95% CI, 14-28).
For the patients at least 8 years old, the mean parental scoring of the global rating of change score was 0.9 6 2.5, and the mean change in youth scoring of the VELO-Y total score was 12 6 13. In this subgroup, 4 parents scored the global rating of change as 21, 0, or 11 corresponding to no change in QOL, and the youth mean change in the VELO-Y total score was 14 6 18. Two parents scored the global rating of change as 23, -2, 12, or 13 corresponding to the anchor for the MCID, and the youth mean magnitude change in the VELO-Y total score was 11 6 15. The secondary MCID analyses of the VELO-P subscales are shown in Table 3 . By the statistical distribution method, the VELO-P total score's MCID was 3 to 7.5.
Change in the VELO Score with VPI Surgery
Subjects in the VPI surgery group reported an improvement in the mean VELO-P total score from 55 6 13 to 76 6 15 (P \ .0001), with improvement in all subscales except perception by others (Bonferroni adjusted, P \ .05) ( Table 4) . VELO-P total scores for the no treatment group also improved from a mean of 49 6 13 at baseline to 58 6 20 (P = .04). Improvements in most subscales in the no treatment group were not statistically significant (Bonferroni adjusted, P . .05) ( Table 4 ).
The VELO-P total score improved more in the VPI surgery group than in the no treatment group ( Table 5) , and this relationship persisted after adjusting for confounders (P = .007). All VELO-P subscale scores improved more in the VPI surgery group than in the no treatment group, but these differences were not statistically significant in this sample ( Table 5 ).
Discussion
One goal of measuring QOL is to understand how treatments affect patients. Patient-centered assessments, such as QOL instruments, are potentially powerful tools for providers and researchers. Understanding how instruments function and how to interpret results is essential. While statistical tests allow for confirming or refuting hypotheses, they do not provide a clinical context for the relevance of changes in QOL scores. Determining the MCID helps identify changes in the VELO-P total score that are clinically important rather than just statistically significant. This study builds on previously conducted validation, reliability, and responsiveness testing 1-3 to determine the MCID for the VELO instrument and rigorously test for change in QOL with VPI surgery.
The MCID analysis is limited by the small sample size in the MCID group. The inclusion of subjects with less definitive treatments (ie, no surgery) or no treatment provided more patients with minimal improvements to supplement the sample for MCID determination. The MCID values determined by the anchor method and linear regression were in good agreement. The difference between this value and that defined in the VELO-Y analysis is likely related to the sample sizes. Because of the larger sample size of the parent group and possibly increased variability among selfreports in younger subjects, it may be wise to place more emphasis on the VELO-P MCID results. The distribution method resulted in a smaller MCID value but is of less clear clinical importance. The correlation of change in the VELO score and the global rating of change measure provides further construct validity for the VELO instrument by showing
that it measures what we intend it to measure. Based on the analyses, the MCID for the VELO-P is likely between 15 and 21. Until further work is done to evaluate the MCID of the VELO-P in a larger sample, it will be considered approximately 15, as that was the primary a priori identified endpoint for the study. The MCID analysis of VELO subscales is also limited by the small sample size. The MCID values are supported by the association with subscale transition measures (P \ .01) ( Table 3 ). The VELO swallowing subscale was skewed, limiting the potential for improvement. Further studies with larger samples are needed to understand the change in VELO subscale scores.
While previous studies have identified a change in QOL or functional status with surgery, 2,6 the favorable change in the VELO score in the no treatment group from baseline to 12 months highlights the importance of a control group. Improvement in the no treatment group was driven by the VELO situational difficulty and caregiver impact subscales. Having a diagnosis may improve some of the psychosocial aspects of QOL and may be reflected in improvements in these subscales. Some of the subjects in the no treatment group received speech therapy, as indicated, which may have improved their speech-related QOL (albeit not statistically significantly).
Subjects who underwent VPI surgery had improvement in the VELO-P total score and all subscale scores, most statistically significant even after applying a correction for multiple testing (paired t test, P \ .05). The change in the VELO-P total score was greater for the VPI surgery group than the no treatment group (P = .02) and remained so after adjusting for confounders (P \ .01). The measured change in the VELO-P total score was above the MCID defined in Test for trend. Figure 1 . Change in the Velopharyngeal Insufficiency Effects on Life Outcomes-Parent (VELO-P) total score versus the global rating of change. Data points shown in black. Black line identifies the mean linear regression estimate, with 95% confidence interval for the regression estimate shown in gray. Global rating of change score ( Table 2) , with higher value representing more improvement.
this study. The MCID and associated analyses provide context for interpreting this change in the VELO-P total score. The mean change in the VELO-P total score after adjusting for confounders (20.3) is near the mean of that in the ''a good deal better'' category of the global rating of change measure (22).
This observational study has important limitations. It is possible that the subjects undergoing surgery had more severe VPI and greater room for improvement in VPI-specific QOL; however, the baseline VELO-P total scores were comparable between the VPI surgery and no treatment groups ( Table 1) , and we adjusted for baseline VPI severity when comparing the groups with multiple linear regression. The risk of unmeasured confounders remains present as with any observational study, but we were deliberate in our inclusion of potential confounders. The improvement in the VPI surgery group compared to the no treatment group remained large and statistically significant after adjusting for confounders. Only a randomized trial can remove entirely the concern of confounding. The follow-up rate of 65% may have introduced bias if those lost to follow-up were systematically different from those followed. However, the baseline characteristics between those followed and those lost to follow-up were not significantly different (data not shown). While it is possible that patients with worse outcomes were more likely not to complete the follow-up questionnaires, we did not observe a pattern of worse outcomes in the clinical follow-up of these patients. Additionally, we mailed our 12-month follow-up questionnaires to help minimize this bias. The present study sought to test the change in self-reported VPI QOL with surgery with the VELO-Y, but the small sample size in the VPI surgery group (n = 3) and the no treatment group (n = 5) limited the power and interpretation. Selfreport with the VELO-Y is important and should be measured when possible. In addition to providing the patient's perspective, it allows for an assessment of differences between parentand youth-reported VPI QOL. These differences might impact treatment decisions, for example, when a child reports impaired swallowing-related QOL about which the parent was otherwise unaware. The full VELO-Y instrument is composed of 23 questions and may be too burdensome to younger patients. Future studies developing a short-form instrument appropriate for youth under 8 years would be of benefit.
The 2 surgical procedures included in the VPI surgery group (Furlow palatoplasty and sphincter pharyngoplasty) may affect VPI-related QOL differently. The cohort was not powered to detect a difference between the surgical techniques. Future studies are needed to test for differences between surgical techniques for treating VPI.
Conclusions
The VELO instrument is a VPI-specific QOL instrument that was developed to capture the way that VPI impacts children's lives. It has previously been tested for validity, reliability, and responsiveness, and now its MCID is defined. Furlow palatoplasty and sphincter pharyngoplasty both improve VPI-specific QOL at a clinically important level when compared to no treatment (or speech therapy alone). The VELO instrument provides a rigorously evaluated QOL instrument for future investigations of VPI treatments with a focus on patient-centered outcomes.
